GLP-1 Evidence

Druga

Semaglutide: cad a léiríonn na trialacha

D'ardaigh semaglutide ag 2.4 mg in aghaidh na seachtaine thart ar 15% caillteanas meánach ar mheáchan comhlacht thar 68 seachtaine. Tá an uimhir sin fíor, athdhéanta, agus go minic míthuiscint.

Updated 4 min read 32 citations Evidence strength 5/5

Táblaí cruinne scaoilte le cód aitheantais, feicthe ó thuas
Larry D. Moore · CC BY 4.0 · Wikimedia Commons

An triala teidil

Rinne STEP 1 daoine fásta le meáchan iomarcach nó murtall agus gan diaibéiteas a randamú chuig semaglutide 2.4 mg in aghaidh na seachtaine nó placebo, beirt le hidirghníomhú stíle saoil, ar feadh 68 seachtaine [9]. Bhí an t-athrú meáchain meánach thart ar −14.9% ar an druga i gcomparáid le −2.4% ar placebo. Thart ar tríú cuid na rannpháirtithe ar an druga chaill 20% nó níos mó de mheáchan comhlacht — toradh a bhí roimhe seo i réimse na máinliacht bariatrach.

Tá dhá rud a bhfuil luach acu le coinneáil. Ar dtús, is meán é sin: tá an dáileadh leathan, agus tá mionlach suntasach ag cailliúint an-chuid. Ar an dara dul síos, fuair an t-arm placebo comhairle ar stíl mhaireachtála freisin, mar sin níl an 2.4% ag "ní dhéanann aon rud" — tomhaistear éifeacht an druga ar bharr comhairle a dhéanann rud éigin.

Tá an uimhir níos lú má tá diaibéiteas ort

Rinne STEP 2 an dearadh céanna i ndaoine fásta le diaibéiteas cineál 2 agus fuair sé thart ar 9.6% caillteanas meáchain ag an dáileog chéanna [8]. Taispeánann an bearna idir thart ar 15% agus thart ar 10% go minic ar fud na ranganna agus ní bhaineann sé go sonrach le semaglutide. Taispeánann anailís comhoiriúnach trasna na GLP-1 agonists an patrún céanna ar an dá thagairt meáchain agus gliceamach [3].

Semaglutide 2.4 mg in aghaidh na seachtaine — athrú meáchain meánach de réir daonra
TrialDaonraTréimhseAthrú meáchain meánPlaic
STEP 1 [9]Obezity, gan diaibéiteas68 seachtaine≈ −14.9%≈ −2.4%
STEP 2 [8]Obezity + diaibéiteas cineál 268 seachtaine≈ −9.6%≈ −3.4%
STEP 4 [7]Leanúnach i gcomparáid le tarraingt siar tar éis 20 seachtaine48 seachtaine breiseLeanúnach: caillteanas breiseTarraingthe siar: athbhuaigh
SELECT [5]Murtall + galar croí agus soithigh~4 blianaSustained ≈ −10%≈ −1.5%

Cé chomh fada agus a choinníonn sé ag obair?

Níos faide ná mar a mhol na trialacha 68-seachtain. Fuair anailís comhoiriúnach ar na sonraí fadtéarmacha go bhfuil an éifeacht á choinneáil go maith thar bliana [1], agus léirigh triala cardiovascular SELECT — a rith thart ar ceithre bliana agus nach raibh deartha mar thrialacha meáchain — go raibh caillteanas meáchain ag pláta ag thart ar 10% agus ansin ag coinneáil, seachas ag dul i laghad [5]. Tá an pláta fíor; níl an t-athrú a thuar na criticeoirí ann, ar choinníonn cóireáil ar aghaidh.

Caillteanas meáchain leanúnach ar chóireáil leanúnach

Semaglutide i gcomparáid le tirzepatide

Do diaibéitis cineál 2, chuir SURPASS-2 tirzepatide i gcomparáid le semaglutide 1 mg agus chuaigh sé i bhfabhar tirzepatide. Do murtall go sonrach, tháinig an comhoibriú díreach ag dáileoga murtall níos déanaí agus bhí sé cinntitheach: tháinig tirzepatide ar chaillteanas meáchain meánach i bhfad níos mó ná semaglutide [10], comhoiriúnach leis na comhoiriúnachtaí réalaíocha agus indíreacha roimhe seo [11].

Ní dhéanann sé sin tirzepatide a dhéanamh mar an rogha cheart do dhuine aonair go huathoibríoch — tá tolra, costais, soláthar agus comhoibrithe uile ag baint leis — ach ar chaillteanas meáchain amháin níl an t-ordú i gcontúirt. Féach tirzepatide.

Áit a bhfuil treoir ag semaglutide ina dhiaidh sin

Thar meáchan, tá semaglutide tar éis dul isteach i treoir foirmiúil do ghalar ae steatóiseach a bhaineann le dysfunction meitibileach, áit a bhfuil na treoirlínte Eorpacha comhoiriúnach ag plé a ról [2]. Is é freisin an t-aon ghníomhaire sa rang le triala toradh cardiovascular críochnaithe i daonra murtall neamh-diaibéitis [5], atá clúdaithe ar an leathanach cardiovascular.

Binse saotharlainne ceimice le gloine agus buidéil réagán in áit
Cjp24 · CC BY-SA 3.0 · Wikimedia Commons

Ceisteanna coitianta

An bhfuil Wegovy difriúil ó Ozempic?
An móilín céanna, dáileog agus comhoiriúnacht ceadaithe difriúil. Úsáid na trialacha murtall 2.4 mg in aghaidh na seachtaine; tá an dáileog do diaibéitis níos ísle. Tagann na méideanna éifeachta a luaitear do chaillteanas meáchain ón dáileog níos airde.
Cén fáth a raibh mé ag cailliúint níos lú ná 15%?
Mar gheall ar 15% is meán é. Athraíonn freagairt go leathan idir daoine aonair i ngach trial, agus cailltear daoine le diaibéitis cineál 2 thart ar tríú cuid níos lú ar an meán [8].
An stopann sé ag obair tar éis cúpla mí?
Níl. Éiríonn an caillteanas meáchain mall agus pláta, de ghnáth thar an dara bliain, ach léiríonn na sonraí fadtéarmacha go gcoimeádtar an caillteanas ar chóireáil leanúnach [1][5].
An féidir liom é a ghlacadh díreach chun cúpla ciliméadar a chailliúint agus ansin stop?
Is féidir leat, ach bí ag súil go dtiocfaidh an chuid is mó den chaillteanas ar ais. Sin é an toradh comhoiriúnach ar na sonraí tarraingthe siar [6][7] agus pléitear é go hiomlán ar an leathanach stop.
An cruthúnas atá taobh thiar den leathanach seo Bar dhíreach a thaispeánann comhoibriú na 12 foilsitheachta a luaitear ar an leathanach seo de réir cineál staidéir. 4101meta-analysis (4)randomised trial (10)other (1)
11 foils, 2021–2025. Is measc é seo le trialacha agus sintéisí ann, atá mar an suíomh óna bhfuil éileamh faoi chúis réasúnta. Téarma: liosta luaiteanna féin an leathanach seo, thíos.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis Karakasis P, Patoulias D, Fragakis N, et al. · Metabolism: clinical and experimental · 2025 · Meta-analysis DOIPubMed 39719170
  2. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOIPubMed 38613667Full text
  3. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Moiz A, Levett JY, Filion KB, et al. · The American journal of cardiology · 2024 · Meta-analysis DOIPubMed 38679221
  4. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) Journal of hepatology · 2024 · Clinical guideline DOIPubMed 38851997
  5. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert opinion on pharmacotherapy · 2024 · Systematic review DOIPubMed 38629387
  6. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis Yao H, Zhang A, Li D, et al. · BMJ (Clinical research ed.) · 2024 · Meta-analysis DOIPubMed 38286487Full text
  7. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review Feier CVI, Vonica RC, Faur AM, et al. · International journal of molecular sciences · 2024 · Systematic review DOIPubMed 38673931Full text
  8. Once-weekly  semaglutide  for obesity  or overweight: A systematic review and meta-analysis He K, Guo Q, Zhang H, et al. · Diabetes, obesity & metabolism · 2022 · Meta-analysis DOIPubMed 34866313
  9. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis Tan HC, Dampil OA, Marquez MM · Journal of the ASEAN Federation of Endocrine Societies · 2022 · Meta-analysis DOIPubMed 36578889Full text
  10. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial Wharton S, Freitas P, Hjelmesæth J, et al. · The lancet. Diabetes & endocrinology · 2025 · Randomised controlled trial DOIPubMed 40961952
  11. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity Wharton S, Lingvay I, Bogdanski P, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40934115
  12. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity Garvey WT, Blüher M, Osorto Contreras CK, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40544433
  13. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes Davies MJ, Bajaj HS, Broholm C, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40544432
  14. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease Cummings JL, Atri A, Feldman HH, et al. · Alzheimer's research & therapy · 2025 · Randomised controlled trial DOIPubMed 39780249Full text
  15. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials Butler J, Shah SJ, Petrie MC, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 38599221Full text
  16. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  17. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Ryan DH, Lingvay I, Deanfield J, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38740993Full text
  18. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial Colhoun HM, Lingvay I, Brown PM, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38796653Full text
  19. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis Bliddal H, Bays H, Czernichow S, et al. · The New England journal of medicine · 2024 · Randomised controlled trial DOIPubMed 39476339
  20. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37952131
  21. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial Kadowaki T, Isendahl J, Khalid U, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35131037
  22. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Garvey WT, Batterham RL, Bhatta M, et al. · Nature medicine · 2022 · Randomised controlled trial DOIPubMed 36216945Full text
  23. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Wilding JPH, Batterham RL, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 35441470Full text
  24. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial Wadden TA, Bailey TS, Billings LK, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33625476Full text
  25. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial Rubino D, Abrahamsson N, Davies M, et al. · JAMA · 2021 · Randomised controlled trial DOIPubMed 33755728Full text
  26. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Davies M, Færch L, Jeppesen OK, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 33667417
  27. Once-Weekly Semaglutide in Adults with Overweight or Obesity Wilding JPH, Batterham RL, Calanna S, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 33567185
  28. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity Friedrichsen M, Breitschaft A, Tadayon S, et al. · Diabetes, obesity & metabolism · 2021 · Randomised controlled trial DOIPubMed 33269530Full text
  29. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial Pratley RE, Aroda VR, Lingvay I, et al. · The lancet. Diabetes & endocrinology · 2018 · Randomised controlled trial DOIPubMed 29397376
  30. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Blundell J, Finlayson G, Axelsen M, et al. · Diabetes, obesity & metabolism · 2017 · Randomised controlled trial DOIPubMed 28266779Full text
  31. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Aronne LJ, Horn DB, le Roux CW, et al. · The New England journal of medicine · 2025 · Clinical trial DOIPubMed 40353578
  32. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. · JAMA internal medicine · 2024 · Journal article DOIPubMed 38976257Full text

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original